Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

64.45USD
26 Jul 2016
Change (% chg)

$0.13 (+0.20%)
Prev Close
$64.32
Open
$64.41
Day's High
$64.73
Day's Low
$63.96
Volume
4,885,238
Avg. Vol
8,273,768
52-wk High
$71.51
52-wk Low
$45.45

ABBV.K

Chart for ABBV.K

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and... (more)

Overall

Beta: 1.48
Market Cap(Mil.): $104,028.50
Shares Outstanding(Mil.): 1,617.36
Dividend: 0.57
Yield (%): 3.54

Financials

  ABBV.K Industry Sector
P/E (TTM): 19.27 36.91 37.71
EPS (TTM): 3.34 -- --
ROI: 18.66 15.22 14.43
ROE: 181.93 16.27 15.61

BRIEF-Abbvie receives U.S. FDA approval of once-daily VIEKIRA XR

* Abbvie receives U.S. FDA approval of once-daily VIEKIRA XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the treatment of genotype 1 chronic Hepatitis C

Jul 25 2016

Samsung Bioepis seeks Europe approval for its Humira copy

SEOUL Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group [SAGR.UL], said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira.

Jul 17 2016

UPDATE 1-Samsung Bioepis seeks Europe approval for its Humira copy

* European Medicines Agency reviewing Samsung Bioepis' application

Jul 17 2016

Blockbuster hopes grow for Ablynx drug backed by AbbVie

Ablynx's hopes for a potential multibillion-dollar drug were boosted on Thursday by strong clinical trial results in rheumatoid arthritis, vindicating a $175 million bet placed on the product by U.S. pharma group AbbVie in 2013.

Jul 07 2016

BRIEF-Biogen and AbbVie's drug approved in EU

* Biogen and AbbVie's once-monthly zinbryta(tm) (daclizumab) approved in European Union for treatment of multiple sclerosis

Jul 05 2016

BRIEF-Biogen and Abbvie's multiple sclerosis drug approved in EU

* Biogen and Abbvie's once-monthly Zinbryta (Daclizumab) approved in European Union for treatment of multiple sclerosis Source text for Eikon: Further company coverage:

Jul 05 2016

BRIEF-Abbvie announces fourth breakthrough therapy designation granted by FDA

* Abbvie announces fourth breakthrough therapy designation granted by the U.S. Food and drug administration (FDA) for ibrutinib (imbruvica) for chronic graft-versus-host-disease (CGVHD), a rare condition with limited treatment options

Jun 29 2016

S&P 500 ends at seven-month high after Yellen comments

The S&P 500 closed at a 7-month high on Monday as Federal Reserve Chair Janet Yellen painted a mostly upbeat picture of the economy but gave little sense of when a rate hike may be coming. | Video

Jun 06 2016

BRIEF-Abbvie reports 17.93 pct passive stake in Reata as of May 25 - SEC filing

* Abbvie Inc reports 17.93 pct passive stake in Reata Pharmaceuticals Inc as of May 25, 2016 - SEC filing Source text for Eikon: [ID:(http://1.usa.gov/1PeZcPg )] Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 06 2016

BRIEF-Moody's downgrades AbbVie to Baa2; stable outlook

* Baa2 rating reflects its large scale with a revenues of about $23 billion, its high margins and its strong cash flow

Jun 01 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $125.15 +0.26
Pfizer Inc. (PFE.N) $36.83 +0.05
Novartis AG (NOVN.S) CHF82.50 +0.30
Merck & Co., Inc. (MRK.N) $58.36 -0.20
Roche Holding Ltd. (ROG.S) CHF250.30 +1.50
Roche Holding Ltd. (RO.S) CHF251.25 +1.25
Abbott Laboratories (ABT.N) $43.60 +0.19
Eli Lilly and Co (LLY.N) $82.09 +0.11
Sanofi SA (SASY.PA) €76.57 +0.06

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.